Thyroid Manager requires free registration
Login or Register

Recent Posts

MORE ON LOW VS HIGH DOSE 131-I ABLATION

Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H. J Clin Endocrinol Metab. 2013 Apr;98(4):1353-60. doi: 10.1210/jc.2012-3682. There is uncertainty over the dose of (131)I required for thyroid remnant ablation.: The aim of this study was to assess […]

Read more »

IGF-1 Receptor antibodies in GO

Autoantibodies to the IGF1 Receptor in Graves' Orbitopathy.Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L. J Clin Endocrinol Metab. 2013 Feb;98(2):752-60. doi: 10.1210/jc.2012-1771 Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving […]

Read more »

SYNTHROID VS GENERICS, AGAIN- EQUIVALENT, OR NOT?? 24 Feb 2013

NO-Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. J Clin Endocrinol Metab. 2013 Feb;98(2):610-7. doi: 10.1210/jc.2012-3125. In the United States, generic substitution of levothyroxine (l-T(4)) by pharmacists is permitted if the formulations are deemed to be bioequivalent by the Federal Drug […]

Read more »

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. J Clin Endocrinol Metab. 2013 Jan;98(1):31-42 The increasing use of tyrosine kinase inhibitor therapy outside of […]

Read more »

RAI ABLATION WITH BRAF+ 1.2CM NODE-NEGATIVE PAPILLARY CANCER?

RAI ABLATION WITH BRAF+ 1.2CM NODE-NEGATIVE PAPILLARY CANCER? 22Jan2013 QUESTION- your opinion on this patient please. 34 yo anesthesiologist noted a midline thyroid nodule 1 month ago, no hx of irradiation to head and neck. us revealed a 1.2 cm hypoechoic nodule at jx of isthmus and right lobe, fna highly suspicious for mjalignancy, 2nd […]

Read more »

Recent Posts

MORE ON LOW VS HIGH DOSE 131-I ABLATION

Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H. J Clin Endocrinol Metab. 2013 Apr;98(4):1353-60. doi: 10.1210/jc.2012-3682. There is uncertainty over the dose of (131)I required for thyroid remnant ablation.: The aim of this study was to assess […]

Read more »

IGF-1 Receptor antibodies in GO

Autoantibodies to the IGF1 Receptor in Graves' Orbitopathy.Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L. J Clin Endocrinol Metab. 2013 Feb;98(2):752-60. doi: 10.1210/jc.2012-1771 Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving […]

Read more »

SYNTHROID VS GENERICS, AGAIN- EQUIVALENT, OR NOT?? 24 Feb 2013

NO-Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. J Clin Endocrinol Metab. 2013 Feb;98(2):610-7. doi: 10.1210/jc.2012-3125. In the United States, generic substitution of levothyroxine (l-T(4)) by pharmacists is permitted if the formulations are deemed to be bioequivalent by the Federal Drug […]

Read more »

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. J Clin Endocrinol Metab. 2013 Jan;98(1):31-42 The increasing use of tyrosine kinase inhibitor therapy outside of […]

Read more »

RAI ABLATION WITH BRAF+ 1.2CM NODE-NEGATIVE PAPILLARY CANCER?

RAI ABLATION WITH BRAF+ 1.2CM NODE-NEGATIVE PAPILLARY CANCER? 22Jan2013 QUESTION- your opinion on this patient please. 34 yo anesthesiologist noted a midline thyroid nodule 1 month ago, no hx of irradiation to head and neck. us revealed a 1.2 cm hypoechoic nodule at jx of isthmus and right lobe, fna highly suspicious for mjalignancy, 2nd […]

Read more »